A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

Urothelial Carcinoma Clinical Trial

Official title:

A Open-Label, Multicenter, Randomised, Controlled Phase 3 Study of RC48-ADC Plus Toripalimab Versus Chemotherapy Alone in Previously Untreated Unresectable Locally Advanced or Metastatic Urothelial Carcinoma With HER2-Expressing

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05302284
• Other study ID #: RC48-C016
• Status: Recruiting
• Phase: Phase 3
• Start date: June 14, 2022
• Est. completion date: April 30, 2028

Study information

• Verified date: December 2023
• Source: RemeGen Co., Ltd.
• Contact: Jianmin Fang, PhD
• Phone: +86-010-58075561
• Email: jianminfang[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 3, Open-Label, Multicenter, Randomised, Controlled Study designed to compare RC48-ADC in Combination With JS001 to Chemotherapy Alone in Previously Untreated HER2-Expressing Unresectable Locally Advanced or Metastatic Urothelial Carcinoma.

Description:

This is a Phase 3, Open-Label, Multicenter, Randomised, Controlled Study to evaluate the efficacy and safety of RC48-ADC,a recombinant humanized anti-HER2 monoclonal antibody-Monomethyl auristatin E (MMAE) conjugate, in Combination With JS001,a PD-1 monoclonal antibody, for the treatment of Previously Untreated HER2-Expressing Unresectable Locally Advanced or Metastatic Urothelial Carcinoma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 452
• Est. completion date: April 30, 2028
• Est. primary completion date: December 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Expected survival =12 weeks.

• Locally advanced unresectable or metastatic UC with histopathological confirmation, including UC originating from the renal pelvis, ureters, bladder, or urethra.

• Participants must not have received prior systemic therapy for locally advanced or metastatic urothelial carcinoma with the following exceptions:

Participants that received neoadjuvant chemotherapy with recurrence >6 months from completion of therapy are permitted; Participants that received adjuvant chemotherapy following cystectomy with recurrence >6 months from completion of therapy are permitted.

• At least one measurable lesion based on RECIST version 1.1

• HER2-expressing status determined by the central laboratory to be IHC 1+, 2+ or 3+.

• ECOG performance status score: 0 or 1.

• Adequate cardiac, bone marrow, hepatic, renal, and coagulation functions.

Exclusion Criteria:

• Known hypersensitivity to RC48-ADC or Toripalimab or any of its components.

• History of major surgery within 4 weeks of planned start of trial treatment.

• Toxicity from a previous treatment has not returned to Grade 0-1.

• Prior ADCs or PD-1/PD-L1 inhibitor therapy.

• Active central nervous system (CNS) metastases.

• Known active hepatitis B, active hepatitis C, or human immunodeficiency virus (HIV) infection.

• History of other malignancy within the previous 5 years, except for low-risk localized prostate cancer, appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or cancers with a similar curative outcome as those mentioned above.

• Other serious, uncontrolled concomitant diseases that may affect protocol compliance or interpretation of outcomes, including active opportunistic infections or advanced (severe) infections, or uncontrolled diabetes.

• Active autoimmune diseases that require systemic therapy over the past 2 years. Replacement therapies (such as thyroxine, insulin, or physiological replacement of glucocorticoids due to renal or pituitary deficiency) are allowed.

• Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Transitional Cell
• Urothelial Carcinoma

Intervention

Drug:
• RC48-ADC
2.0 mg/kg IV every 2 weeks
• Toripalimab
3.0 mg/kg IV every 2 weeks
• Gemcitabine
1000mg/m2 IV infusion on Days 1 and 8 of every 3 week cycle
• Cisplatin
70mg/m2 IV infusion on Day 1 of every 3 week cycle
• Carboplatin
AUC=4.5, IV infusion on Day 1 of every 3 week cycle

Locations

Country	Name	City	State
China	Beijing Cancer Hospital	Beijing
China	Cancer Hospital Chinese Academy of Medical Sciences	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
RemeGen Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival (PFS), evaluated by independent review committee	Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by independent review committee according to the RECIST 1.1 standard.	Up to approximately 3 years
Primary	Overall survival (OS)	Overall survival (OS) refers to the time from the date of randomization to the date of death of the subject.	Up to approximately 3 years
Secondary	Objective remission rate (ORR)	The objective response rate will be mainly analyzed by the independent efficacy evaluation committee according to the RECIST 1.1 standard tumor evaluation (the evaluation by the investigator will also be performed).	Up to approximately 3 years
Secondary	Progression-free survival (PFS), evaluated by the investigator	Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard.	Up to approximately 3 years
Secondary	Duration of relief (DOR)	DOR is defined as the time from the first documented objective response (CR or PR) to the first documented disease progression or death	Up to approximately 3 years
Secondary	Disease control rate (DCR)	Disease control rate (DCR) is defined as cases where objective remission (assessed as complete remission or partial remission according to RECIST 1.1 standard) or stable disease during the study.	Up to approximately 3 years